Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial

  • Meredith M. Regan
  • , Opeyemi A. Jegede
  • , Charlene M. Mantia
  • , Thomas Powles
  • , Lillian Werner
  • , Robert J. Motzer
  • , Nizar M. Tannir
  • , Chung Han Lee
  • , Yoshihiko Tomita
  • , Martin H. Voss
  • , Elizabeth R. Plimack
  • , Toni K. Choueiri
  • , Brian I. Rini
  • , Hans J. Hammers
  • , Bernard Escudier
  • , Laurence Albiges
  • , Stephen Huo
  • , Viviana Del Tejo
  • , Brian Stwalley
  • , Michael B. Atkins
    • David F. McDermott

Research output: Contribution to journal › Article › peer-review

50 Scopus citations

Fingerprint

Dive into the research topics of 'Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial'. Together they form a unique fingerprint.

Nursing and Health Professions

Pharmacology, Toxicology and Pharmaceutical Science